Avdoralimab (Anti-C5aR1 mAb) Versus Placebo in Patients With Severe COVID-19: Results From a Randomized Controlled Trial (FOR COVID Elimination [FORCE]).

ABSTRACT:

Objectives

Severe COVID-19 is associated with exaggerated complement activation. We assessed the efficacy and safety of avdoralimab (an anti-C5aR1 mAb) in severe COVID-19.

Design

FOR COVID Elimination (FORCE) was a double-blind, placebo-controlled study.

Setting

Twelve clinical sites in France (ICU and general hospitals).

Patients

Patients receiving greater than or equal to 5 L oxygen/min to maintain Sp o2 greater than 93% (World Health Organization scale ≥ 5). Patients received conventional oxygen therapy or high-flow oxygen (HFO)/noninvasive ventilation (NIV) in cohort 1; HFO, NIV, or invasive mechanical ventilation (IMV) in cohort 2; and IMV in cohort 3.

Interventions

Patients were randomly assigned, in a 1:1 ratio, to receive avdoralimab or placebo.

SUBMITTER: Carvelli J 

PROVIDER: S-EPMC9674430 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature